NCT05464173: Chidamide in Combination With Abemaciclib and Fulvestrant in Breast Cancer Patients Previously Treated With Palbociclib

NCT05464173
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with prior chemotherapy or fulvestrant (or fulvestrant-resistant) for recurrent or metastatic breast cancer; Patients with more than 3 lines of prior endocrine therapy; Patients with prior HDAC inhibitor therapy or any other CDK inhibitor that is not Ibrance (e.g. Kisqali/ribociclib, Verzenio/abemaciclib); Patients that have not progressed while taking Ibrance/palbociclib in the neoadjuvant setting or at least 6 months into the metastatic setting; Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease
https://ClinicalTrials.gov/show/NCT05464173

NCT05468359: Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

NCT05468359
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy, Chemotherapy, Serine-Threonine Kinase Inhibitor, Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: up to 30 Years (Child, Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for Part 1 of the study
Exclusions: Patients over the age of 30 years; Patients with tumors not safely accessible by biopsy
https://ClinicalTrials.gov/show/NCT05468359

Up ↑